Physician profile
Anna Eremieva
NPI 1750316634
$2,927.89
in general payments reported to CMS, 2019-2025
25 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.98 · 2022: $17.23 · 2023: $294 · 2024: $1,211 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.10 | 2023-2025 | |
| Pfizer INC. | $416.28 | 2024-2025 | |
| Amgen INC. | $250.88 | 2022-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $215.78 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $205.42 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $133.18 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Mylan Specialty L.P. | $100.89 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.86 | 2024-2025 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $96.81 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $87.27 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $86.47 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $78.64 | 2024-2025 | |
| Astellas Pharma US INC | $78.12 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $59.47 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.27 | 2025 | Caplyta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.51 | 2024-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $32.73 | 2025 | Symbravo |
| Lundbeck LLC | $24.57 | 2024 | Rexulti |
| Abbott Laboratories | $23.90 | 2024 | Freestyle Libre |
| Inspire Medical Systems, INC. | $20.40 | 2025 | Inspire |
| Allergan, INC. | $18.98 | 2020 | |
| Dynavax Technologies Corporation | $18.68 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $18.56 | 2025 | Voquezna |
| Ironshore Pharmaceuticals INC. | $15.35 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.77 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Eremieva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.